Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed/refractory acute myeloid leukemia

2026/03/03 by Marco Becilli, Pietro Merli, Mattia Algeri +15 · 2 citations
Medicine · Immunology and Microbiology · #CAR-T cell therapy research #Acute Lymphoblastic Leukemia research #Immune Cell Function and Interaction

paper · doi:10.1182/blood.2025032299

Abstract

ABSTRACT: Autologous second-generation CD7-directed chimeric antigen receptor T cells, expressing an anti-CD7 protein expression blocker to prevent self-killing fratricide, were infused in 3 pediatric/young adult patients with relapsed/refractory CD7+ acute myeloid leukemia, resulting in measurable residual disease negativity. The safety profile was favorable.

Citations

• T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Cited by

• Overcoming disease refractoriness through CD7-targeting CAR T cells in acute myeloid leukemia. [europepmc]
• Olive Leaf Extract Health-Promoting and Anti-Tumor Properties: An Adjunct Therapy in Pediatric Oncology? [europepmc]

Related

• CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML
• Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
• Base edited “universal” donor CAR T cell strategies for acute myeloid leukaemia
• Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system
• Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias